Trial Profile
Safety and transdermal water loss value in patients with non-small cell lung carcinoma who treated with gefitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
- 07 Apr 2017 New trial record
- 01 Mar 2017 Results published in the Dermatology and Therapy